Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
Johnson & Johnson seeks FDA approval of IMAAVY® as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia
TREMFYA® long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
RYBREVANT FASPRO plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
RYBREVANT FASPRO receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments
CORRECTION FROM SOURCE: Video - CEO Clips Bold Ventures Advances Exploration at Burchell and Highlights Ring of Fire
Bold Ventures Provides Update on Burchell Drilling Progress and Announces PDAC Participation at Booth #2610
